TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06755528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan
Description: The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: The participants will receive shockwave with the following parameters: sonic pulses characterized by: high peak pressure, up to 100 mpa (500 bar) or even more, rapid rise in pressure (\<10 ns), short duration (\<10 μs) and a broad range of frequency. The energy flux density was 0.09 to 0.16 mJ/mm2; with a frequency of 5 Hz and 2000 impulses, i session per week for 4 weeks.
Study: NCT06757634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Description: Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off~Other Names:~• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks~Other Names:~• Faslodex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Description: Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off~Other Names:~• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks~Other Names:~• Faslodex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: Palbociclib or Ribociclib + Fulvestrant
Description: Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI®~Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4~Other Names:~• Faslodex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm B: Palbociclib or Ribociclib + Fulvestrant
Description: Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI®~Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4~Other Names:~• Faslodex
Study: NCT06757400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manipulation
Description: Manipulation will be conducted on an examination table with the subject in right lateral decubitus. It will be a rotary manipulation to the most hypomobile lumbar spine segment after assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manipulation
Description: Manipulation will be conducted on an examination table with the subject in right lateral decubitus. It will be a rotary manipulation to the most hypomobile lumbar spine segment after assessment.
Study: NCT06758362

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: A structured psychotherapy approach focused on reducing PTSD symptoms through guided eye movements and trauma processing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A psychotherapy approach focused on identifying and modifying maladaptive thought patterns and behaviors to reduce PTSD symptoms.
Study: NCT06758518

Intervention type: OTHER
Intervention: No Interventions
Description: there will be no intervention
Study: NCT06759766

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic-Lemon Extract irrigant
Description: garlic (Allium sativum) Shows a wide range of therapeutic effects due to the presence of allicin, ajoene \& other thiosulfinates. It has antibacterial effect against wide range of gram-positive and gram-negative bacteria, anti-inflammatory, antioxidant, antiviral, antifungal, antitumor, immunomodulatory effects and tissue-dissolving capacity (Siddique, et al., 2020). According to (Elheeny., 2019) Allium sativum extract can be used efficiently as an irrigant for pulpectomy of primary molar root canals.~Lemon (Citrus Limon) as well has curative properties such as, antibacterial, antiviral, antifungal, anti-inflammatory, anti-cancerous activities and removal of the smear layer as well. Due to presence of ascorbic acid, phenolic acids, polyphenols, and dietary fibers.~the combination of Garlic-Lemon has been tested in adult teeth as an irrigant and showed an effective result equal to NaOCl (Siddique, et al., 2020).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiological saline
Description: Normal saline solution exhibits no adverse effects on the developing successors; Serves primarily to facilitate root canal cleaning during the irrigation process, in comparison to other commercial synthetic irrigants such as Sodium hypochlorite (NaOCl), Chlorhexidine (CHX), Ethylenediamine tetra acetic acid (EDTA) which exhibit potential side effects and cytotoxic reactions (Sayadizadeh et al., 2019).
Study: NCT06760195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-arterial hypothermic magnesium sulfate infusion
Description: According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 330 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 30 ml MgSO4 solution will be infused into the ischemic territory at 15 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Description: All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
Study: NCT06761170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spray cryo therapy
Description: normal flow, 5 seconds repeated for 3-5 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: 1. Steroid injection~2. Radial mucosal incision~3. Balloon dilation (to normal airway diameter)
Study: NCT06762652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wash-in period
Description: The goal of the wash-in period between the control and intervention period is to intensively educate and train physicians to use the algorithm as intended during daily postoperative care. The coordinating investigator along with the local principal investigator will be responsible for this training. Training will be performed in a standardized approach in order to guarantee uniformity across centres.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm-based care
Description: During the intervention period, (participating) patients will receive algorithm-based care. The RESCUE algorithm is a consensus-based clinical care algorithm developed to standardize postoperative care. The algorithm includes the same modalities as applied in usual care, and does not include novel/experimental modalities, but rather offers a novel, standardized approach to guide the use of common modalities during postoperative care. The daily objective evaluation of patients' condition, vital signs and biochemical parameters is thought to aid early diagnosis of complications after esophagectomy which enables treatment before systemic symptoms become apparent and prevent development of sepsis. Physicians are always allowed to deviate from the RESCUE, but reasons for deviating will be recorded.
Study: NCT06761560

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic based dosage change
Description: This study will compare 2 groups of sickle cell patients that are receiving hydroxyurea. Group A will have an increase in their dosage based on the pharmacokinetic result over a period of 12 months and Group B will have an increase in their dosage based on the standard of care follow-up over a period of 12 months. The aim is to evaluate if the group A can reach MTD faster than than the Group B

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic dosing
Description: Patient with sickle cell disease will undergo one pharmacokinetic test after taking 12 months of hydroxyurea to evaluate HU-AUC at that timepoint
Study: NCT06761131

Intervention type: DRUG
Intervention: Linezolid (LZD)
Description: compare the incidence and magnitude of Linezolid induced thrombocytopenia

Intervention type: DRUG
Intervention: Linezolid (LZD)
Description: compare the incidence and magnitude of Linezolid induced thrombocytopenia
Study: NCT06760741

Intervention type: GENETIC
Intervention: Multigene panel
Description: Germline Genetic Testing: Germline genetic testing will be performed on all patients with pancreatic cancer (PC) using a custom multigene panel. This panel includes 25 candidate genetic variants of interest and 13 clinically recognized genes associated with a higher risk of PC.~DNA Extraction: Germline DNA will be extracted from peripheral blood samples using the QIAamp DNA Blood Kit (Qiagen, Redwood City, CA, USA) following the manufacturer's instructions. The concentration of double-stranded DNA will be measured using a fluorometric method (Qubit, Thermo Fisher Scientific).

Intervention type: DIAGNOSTIC_TEST
Intervention: Other
Description: 1. Characterization of Suspected Pancreatic Cancer Lesions:~   Characterization of suspected pancreatic cancer (PC) lesions identified by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) in patients undergoing screening since 2014. This includes lesion type (solid or cystic), rapid cyst growth exceeding 4 mm per year, location, size, potential assessment of resectability, lobulocentric parenchymal atrophy, and Wirsung duct dilation. Clinically relevant suspected lesions will be defined as solid lesions, intraductal papillary mucinous neoplasms (IPMN), cystic lesions ≥10 mm, and cystic lesions with mural nodules.~2. Determination of CA 19-9 and Glycated Hemoglobin:~Measurement of CA 19-9 levels and glycated hemoglobin (HbA1c) as part of the diagnostic and monitoring process.

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA measurement in blood
Description: Analysis of miRNA Expression in plasma:~The expression of circulating miRNAs (in plasma) will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The signature includes two miRNAs (miR-33a-3p and miR-320a) combined with CA 19-9.

Intervention type: GENETIC
Intervention: Generation of 3D Pancreatic Organoids
Description: Generation of 3D Pancreatic Organoids for Complementary Analyses:~3D pancreatic organoids will be generated for complementary analyses involving in vitro functional studies to evaluate the pathogenicity of novel genes (selected based on the results of the multigene panel). These organoids will be developed from surgical samples obtained from five patients undergoing surgery as part of clinical care.
Study: NCT06761313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination formula
Description: Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost .03% sterile ophthalmic solution
Description: Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate 0.2%(1 drop twice a day), Timolol Maleate 0.5% (1 drop twice a day) and Bimatoprost 0.3% (1 drop at night). At the first visit a complete ophthalmolgical exam which includes ocular surface items (conjunctival hiperemia, keratitis and tear film break up time). Questionnaires are performed (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire) to assess information about ocular surface adverse effects, quality of life and treatment adherence. Glaucoma exams as retinography, perimetry, optic nerve OCT (optical coherence tomography), central corneal thickness are performed on all patients to evaluate disease's control. This procedure will be repeated at all visits: baseline and within 4, 8, 12 weeks.
Study: NCT06762613

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Generative AI Based Puncture Surgery Navigation System
Description: Participants will receive percutaneous lung puncture under the guidance of GPS.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cone beam CT
Description: Participants will receive percutaneous lung puncture under the guidance of cone beam CT.
Study: NCT06761391

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Pain Pressure Threshold
Description: A hand-held pressure algometer will be used to record the pressure pain threshold (PPT), defined as the level at which gradually increasing pressure becomes painful. Pressure algometry has shown high intratest reliability in asymptomatic individuals over the suboccipital area and upper trapezius. PPT levels will be measured bilaterally over the neck angle over the middle of the anterior surface of the upper trapezius; and over the rectus capitis posterior major (RCPM) muscle. The physiotherapist will use an increasing pressure of approximately 1 kg/cm²/s. The average of three measurements with a 30-second rest period will be taken for analysis. Two measurements will be taken, before and after.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pain Pressure Threshold
Description: A hand-held pressure algometer will be used to record the pressure pain threshold (PPT), defined as the level at which gradually increasing pressure becomes painful. Pressure algometry has shown high intratest reliability in asymptomatic individuals over the suboccipital area and upper trapezius. PPT levels will be measured bilaterally over the neck angle over the middle of the anterior surface of the upper trapezius; and over the rectus capitis posterior major (RCPM) muscle. The physiotherapist will use an increasing pressure of approximately 1 kg/cm²/s. The average of three measurements with a 30-second rest period will be taken for analysis. Two measurements will be taken, before and after.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Cervical Range of Motion
Description: The degrees obtained as a result of the Range of Motion (ROM) measurements are made with a universal manual goniometer. Goniometer is still the most commonly used method for ROM measurements. For all ROM measurements to be performed, the necessary measurements can be taken based on the American Academy of Orthopaedic Surgeons (AAOS) guidelines . The flexion, extension, right and left rotation angles of the cervical region will be measured and recorded with the goniometer in the sitting position of the person. The measurement will be made twice, before and after the application.
Study: NCT06128564

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec
Study: NCT06415175

Intervention type: DRUG
Intervention: Dupilumab
Description: This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
Study: NCT05976763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zanubrutinib
Description: Given PO
Study: NCT06761079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar interfascial plane block
Description: Ultrasound-guild bilateral Thoracolumbar interfascial plane block with a total 40 ml, 0.25% bupivacaine by anesthesiologist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration
Description: 0.25%bupivacaine infiltration at surgical wound site by orthopedic surgeon
Study: NCT06762145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Corticosteroid)
Description: Intravenous Methylprednisolone 1mg/kg/d for 3 days started from the day on TAVR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 days started from the day on TAVR
Study: NCT06762353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-month supportive peri-implant care (SPIC)
Description: SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 3-month frequency after surgical treatment of peri-implantitis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6-month supportive peri-implant care (SPIC)
Description: SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 6-month frequency after surgical treatment of peri-implantitis.
Study: NCT06761222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of ultrasound in central blocks
Description: Ultrasonography was conducted using a convex probe in the paramedian and transverse planes.
Study: NCT06761781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Each participant will receive a standard trial consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Each session will consist of 2-10 exercises selected by the trainer from a pool of 46 exercises. The selected exercises will be tailored based on the participant's condition and progress. The exercise pool will be designed as comprehensively as possible to cover the upper limb (22 exercises and lower limb (7 exercises) motor functions, balance ability (11 exercises), or/and coordination (6 exercises).~Each exercise with a duration ranging from 3 to 23 min, and will be determined by a set of parameters that can be adjusted to the individuals dynamically according to the participant's performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Description: Each participant will receive a Traditional training based on Task oriented training consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Exercises will be tailored based on the participant's condition and progress. The exercises will cover the upper limb, lower limb, motor functions, balance ability and coordination.
Study: NCT06761729

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet
Study: NCT06762132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33 CAR T-cells
Description: Each subject receive CD33 CAR T-cells by intravenous infusion
Study: NCT06002854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP( platelet rich plasma) and Insulin human
Description: Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP( platelet rich plasma) and Insulin human
Description: Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation